bioAffinity Technologies (BIAF) Return on Sales (2022 - 2026)

bioAffinity Technologies (BIAF) has 5 years of Return on Sales data on file, last reported at 0.03% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.03%, down 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.03% (down 2.0% YoY), and the FY2025 annual result was 0.02%, down 1.0% from the prior year.
• Return on Sales fell to 0.03% in Q1 2026 per BIAF's latest filing, from 0.02% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q1 2024 and troughed at 42.78% in Q3 2022.
• A 5-year average of 4.27% and a median of 0.03% in 2025 frame the typical range for Return on Sales.
• On a YoY basis, Return on Sales climbed as much as 4270 bps in 2023 and fell as far as 21 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 7.14% in 2022, then surged by 100 bps to 0.01% in 2023, then dropped by 25 bps to 0.01% in 2024, then tumbled by 47 bps to 0.02% in 2025, then tumbled by 36 bps to 0.03% in 2026.
• Business Quant data shows BIAF's Return on Sales at 0.03% in Q1 2026, 0.02% in Q4 2025, and 0.03% in Q3 2025.